Which has better earnings & valuation, RZLT or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is RZLT or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Hemab Therapeutics N/A N/A N/A

Does the media prefer RZLT or COAG?

In the previous week, Rezolute had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for Hemab Therapeutics. Rezolute's average media sentiment score of 0.84 beat Hemab Therapeutics' score of 0.61 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to WVE or RZLT?

In the previous week, Rezolute had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for WAVE Life Sciences. Rezolute's average media sentiment score of 0.84 beat WAVE Life Sciences' score of 0.32 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, RZLT or MPLT?

Rezolute is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is RZLT or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Maplight Therapeutics N/A N/A N/A

Does the media prefer RZLT or MPLT?

In the previous week, Maplight Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 14 mentions for Maplight Therapeutics and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.84 beat Maplight Therapeutics' score of 0.16 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RZLT or PAHC?

In the previous week, Rezolute had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 8 mentions for Rezolute and 6 mentions for Phibro Animal Health. Rezolute's average media sentiment score of 0.84 beat Phibro Animal Health's score of 0.84 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RZLT or MRVI?

In the previous week, Rezolute had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Rezolute and 3 mentions for Maravai LifeSciences. Rezolute's average media sentiment score of 0.84 beat Maravai LifeSciences' score of 0.82 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rezolute (RZLT) Competitors

$4.58 +0.58 (+14.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.52 -0.06 (-1.22%)

As of 07:52 PM Eastern

Compare

RZLT vs. COAG, WVE, MPLT, PAHC, and MRVI

Should you buy Rezolute stock or one of its competitors? MarketBeat compares Rezolute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rezolute include Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), Maplight Therapeutics (MPLT), Phibro Animal Health (PAHC), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Rezolute compare to Hemab Therapeutics?

Rezolute (NASDAQ:RZLT) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Rezolute had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for Hemab Therapeutics. Rezolute's average media sentiment score of 0.84 beat Hemab Therapeutics' score of 0.61 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rezolute presently has a consensus target price of $8.75, suggesting a potential upside of 91.05%. Hemab Therapeutics has a consensus target price of $41.75, suggesting a potential upside of 59.53%. Given Rezolute's higher probable upside, research analysts plainly believe Rezolute is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics' return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Hemab Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Rezolute beats Hemab Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Rezolute compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Rezolute had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for WAVE Life Sciences. Rezolute's average media sentiment score of 0.84 beat WAVE Life Sciences' score of 0.32 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences presently has a consensus price target of $27.25, indicating a potential upside of 373.09%. Rezolute has a consensus price target of $8.75, indicating a potential upside of 91.05%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Rezolute has lower revenue, but higher earnings than WAVE Life Sciences. Rezolute is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.94	-$204.38M	-$1.06	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Rezolute has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Rezolute	N/A	-58.82%	-54.48%

Summary

WAVE Life Sciences beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Maplight Therapeutics?

Rezolute (NASDAQ:RZLT) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Maplight Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 14 mentions for Maplight Therapeutics and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.84 beat Maplight Therapeutics' score of 0.16 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rezolute presently has a consensus target price of $8.75, indicating a potential upside of 91.05%. Maplight Therapeutics has a consensus target price of $37.78, indicating a potential upside of 33.30%. Given Rezolute's higher possible upside, equities analysts clearly believe Rezolute is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

Maplight Therapeutics' return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Rezolute and Maplight Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Rezolute compare to Phibro Animal Health?

Rezolute (NASDAQ:RZLT) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Rezolute had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 8 mentions for Rezolute and 6 mentions for Phibro Animal Health. Rezolute's average media sentiment score of 0.84 beat Phibro Animal Health's score of 0.84 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rezolute currently has a consensus price target of $8.75, indicating a potential upside of 91.05%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 22.05%. Given Rezolute's stronger consensus rating and higher probable upside, equities research analysts clearly believe Rezolute is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Phibro Animal Health has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Phibro Animal Health	$1.30B	0.99	$48.26M	$2.33	13.64

Rezolute has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Rezolute's net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Maravai LifeSciences?

Rezolute (NASDAQ:RZLT) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Rezolute has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Rezolute currently has a consensus target price of $8.75, indicating a potential upside of 91.05%. Maravai LifeSciences has a consensus target price of $5.50, indicating a potential upside of 13.64%. Given Rezolute's stronger consensus rating and higher probable upside, research analysts plainly believe Rezolute is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Rezolute had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Rezolute and 3 mentions for Maravai LifeSciences. Rezolute's average media sentiment score of 0.84 beat Maravai LifeSciences' score of 0.82 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Maravai LifeSciences	$185.74M	6.73	-$130.77M	-$0.71	N/A

Rezolute has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rezolute beats Maravai LifeSciences on 10 of the 15 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$385.17M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-5.59	9.91	18.89	22.53
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	2.46	6.63	9.84	6.72
Net Income	-$74.41M	$24.20M	$3.57B	$337.19M
7 Day Performance	37.95%	-3.24%	-1.16%	0.48%
1 Month Performance	38.79%	0.53%	3.85%	5.07%
1 Year Performance	3.62%	47.24%	27.40%	34.25%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.892 of 5 stars	$4.58 +14.5%	$8.75 +91.0%	-5.2%	$385.17M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up High Trading Volume
COAG Hemab Therapeutics	4.8047 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	News Coverage Short Interest Increase
WVE WAVE Life Sciences	2.6757 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-9.0%	$1.27B	$71.80M	N/A	240
MPLT Maplight Therapeutics	3.7681 of 5 stars	$29.76 +1.5%	$37.78 +26.9%	N/A	$1.25B	N/A	N/A	109	Analyst Forecast Analyst Revision
PAHC Phibro Animal Health	4.8279 of 5 stars	$29.87 -3.0%	$38.80 +29.9%	+16.0%	$1.25B	$1.50B	12.82	2,475

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Rezolute compare to Hemab Therapeutics?

Summary

How does Rezolute compare to WAVE Life Sciences?

Summary

How does Rezolute compare to Maplight Therapeutics?

Summary

How does Rezolute compare to Phibro Animal Health?

Summary

How does Rezolute compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Rezolute compare to Hemab Therapeutics?

Does the media prefer RZLT or COAG?

Do insiders and institutionals hold more shares of RZLT or COAG?

Do analysts rate RZLT or COAG?

Is RZLT or COAG more profitable?

Which has better earnings & valuation, RZLT or COAG?

Summary

How does Rezolute compare to WAVE Life Sciences?

Does the media refer more to WVE or RZLT?

Do analysts prefer WVE or RZLT?

Which has more volatility and risk, WVE or RZLT?

Do insiders & institutionals believe in WVE or RZLT?

Which has better valuation and earnings, WVE or RZLT?

Is WVE or RZLT more profitable?

Summary

How does Rezolute compare to Maplight Therapeutics?

Does the media prefer RZLT or MPLT?

Which has higher valuation & earnings, RZLT or MPLT?

Do institutionals & insiders hold more shares of RZLT or MPLT?

Do analysts recommend RZLT or MPLT?

Is RZLT or MPLT more profitable?

Summary

How does Rezolute compare to Phibro Animal Health?

Does the media favor RZLT or PAHC?

Do insiders & institutionals hold more shares of RZLT or PAHC?

Do analysts prefer RZLT or PAHC?

Which has stronger earnings and valuation, RZLT or PAHC?

Which has more risk & volatility, RZLT or PAHC?

Is RZLT or PAHC more profitable?

Summary

How does Rezolute compare to Maravai LifeSciences?

Is RZLT or MRVI more profitable?

Do analysts prefer RZLT or MRVI?

Does the media favor RZLT or MRVI?

Which has better valuation and earnings, RZLT or MRVI?

Which has more volatility & risk, RZLT or MRVI?

Do insiders and institutionals hold more shares of RZLT or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools